Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03990129
Other study ID # 2018-00753
Secondary ID
Status Completed
Phase Phase 1
First received
Last updated
Start date September 4, 2018
Est. completion date October 31, 2018

Study information

Verified date June 2019
Source University Hospital, Basel, Switzerland
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Investigators conducted a single center, two-phased, open, controlled pharmacokinetic study to investigate the drug-drug interaction potential of metamizole. For this reason, healthy male volunteers were screened.

Enrolled participants were phenotyped on day 1 using the Basel Cocktail (phenotyping cocktail containing specific substrates for CYP1A2, CYP2B6, CYP2C9, CYP2C19, CYP2D6, CYP3A4). After, they received metamizole treatment for 8 days (3 grams per day). On the 8th day (day 9), they were phenotyped again with the Basel Cocktail and the respective phenotypes (d1 vs. d9) were compared.


Description:

12 healthy male subjects meeting the inclusion and exclusion criteria were enrolled. On day 1, they ingested a capsule containing the Basel Cocktail (1A2: caffeine, 2B6: efavirenz, 2C9: flurbiprofen, 2C19: omeprazole, 2D6: metoprolol, 3A4: midazolam) in fastened state. Blood samples were withdrawn over 24 hours and the AUC ratios between metabolite and parent were calculated to determine the phenotype.

Probands began metamizole treatment (3000 mg/day) at the day of the 24h measurement. After 3-4 day, probands were returning to the facility to ensure safety during the metamizole treatment, blood cell count and metamizole metabolites were measured. After the 7 days of treatment, probands were exposed again to the Basel Cocktail in a fastened state. Probands were still exposed to metamizole to ensure potential inhibition. 24 hours plasma samples were withdrawn, area under the curve (AUC) ratios were calculated and compared to the basal state. After an end of study visit on the day of the 24h blood sample (following the second study day), probands were discharged.


Recruitment information / eligibility

Status Completed
Enrollment 12
Est. completion date October 31, 2018
Est. primary completion date October 31, 2018
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Male
Age group 18 Years to 45 Years
Eligibility Inclusion Criteria:

- Healthy subjects aged between 18 and 45 years (inclusive) at screening

- BMI between 18 and 28 kg/m2 (inclusive) and bodyweight at least 50 kg at screening

- systolic blood pressure: 100-140 mmHg, diastolic blood pressure: 60-90 mmHg and heart rate: 45-90 bpm (inclusive), measured on the leading arm, in the supine position at screening

- No clinically significant findings on the physical examination at screening

- Signed informed consent prior to any study-mandated procedure

- Hematology and clinical chemistry results not deviating from the normal range to clinically relevant extent at screening

- Ability to communicate well with the investigator to understand and comply with the requirements of the study

Exclusion Criteria:

- Smoking >5 cigarettes per day

- History or clinical evidence of alcoholism or drug abuse within the 3- year period prior to screening

- Loss of =250 ml of blood within 3 months prior to screening. Treatment with an investigational drug within 30 days prior to screening

- Previous systemic treatment with any prescribed or over the counter medication (including herbal medicines such as St John's Wort) within 2 weeks prior to the intended start of the study

- Inability to stop consumption inducing food products (e.g. grapefruit juice) 72 h before start of the study

- Excessive caffeine consumption (>8 cups of coffee/ 8l coca cola per day)

- Legal incapacity or limited legal capacity at screening

- Positive results from urine drug screen at screening

- History or clinical evidence of any disease (e.g. gastrointestinal disease: Morbus Crohn, Colitis Ulcerosa, anamnestic gastrointestinal bleeding) and/or existence of any surgical or medical condition, which might interfere with the absorption, distribution, metabolism or excretion of the study drugs, or which might increase the risk for toxicity

- Known hypersensitivity to Metamizole (Novalgin®) or excipients of the drug formulation

- Any circumstances or conditions, which, in the opinion of the investigator, may affect full participation in the study or compliance with the protocol.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Metamizole
One week treatment with metamizole (500 mg tablets, 2-2-2)

Locations

Country Name City State
Switzerland Clinical Trial Unit, University Hospital Basel Basel BS

Sponsors (1)

Lead Sponsor Collaborator
University Hospital, Basel, Switzerland

Country where clinical trial is conducted

Switzerland, 

Outcome

Type Measure Description Time frame Safety issue
Primary Effect on AUC ratio between parent and metabolite AUC ratio between parent and metabolite of specific cytochrome P450 substrates to determine a shift which may indicate either induction or inhibition of the specific cytochrome P450 12 hours
Primary Cmax Maximal Concentration in plasma of parent and metabolite 24 hours
Primary tmax time to reach Cmax 24 hours
See also
  Status Clinical Trial Phase
Completed NCT05692570 - A Study of PBI-200 With Ritonavir or Cobicistat in Healthy Volunteers Phase 1
Completed NCT04328766 - Pharmacokinetic Interaction Between DWP14012 and DWC202005 in Healthy Volunteers Phase 1
Completed NCT03985969 - Study to Investigate the Potential Drug-Drug Interaction Between Elafibranor and Indomethacin Phase 1
Completed NCT03302845 - A Phase 1 Study to Evaluate the Effects of Omeprazole and Famotidine on the Absorption of Telotristat Ethyl in Healthy Subjects Phase 1
Completed NCT02887443 - A Study to Assess the Potential for Pre-systemic Inhibition of CYP3A by Idebenone Using Midazolam as a Substrate Phase 1
Completed NCT01361217 - The Effects of Multiple Dose Fluoxetine and Metabolites on CYP1A2, CYP2C19, CYP2D6 and CYP3A4 Activity N/A
Completed NCT06066060 - A DDI Study of JMKX000623 and Metformin Hydrochloride Phase 1
Completed NCT03723395 - A Drug-Drug Interaction Study in Healthy Volunteers of the Effects of Tucatinib Phase 1
Recruiting NCT05789173 - Interaction of CYP2B6 Genotype and Efavirenz With Methadone and Tizanidine PK Early Phase 1
Completed NCT04598542 - Drug-Drug Interaction Study of Lorecivivint and Triamcinolone Acetonide in Healthy Volunteers Phase 1
Recruiting NCT05044962 - Kuwa Free! - Live Free! N/A
Completed NCT04487145 - Dihydroartemisinin-Piperaquine in the Context of Antiretroviral Therapy Phase 4
Completed NCT05108051 - Study to Investigate the Potential Drug-Drug Interaction Between ZSP1273 and Oseltamivir Phase 1
Active, not recruiting NCT04669678 - Evaluation of Pharmacokinetic Drug-drug Interactions Between Hormonal Contraceptives and Doravirine-containing ART Among Women Living With HIV in South Africa Phase 4
Completed NCT01991327 - Assessment of Drug-Drug Interactions of Androxal With Cytochrome P450 Isoenyzmes in Healthy Males Phase 1
Completed NCT04218513 - Drug-drug Interaction Study Between Edaravone and 2-Aminoethanesulfonic Acid in Compound Edaravone Injection Phase 1
Completed NCT05492318 - Perpetrator DDI Potential of Givinostat as Inhibitor and Inducer of CYP3A and P-gp Activity Phase 1
Completed NCT01309854 - Effects of Administration of Fostamatinib on Blood Concentrations of Pioglitazone in Healthy Subjects Phase 1
Recruiting NCT05339672 - Determining the Clinical Relevance of the Interaction Between Enzalutamide and the Opioid Morphine and the DOAC Edoxaban
Completed NCT05306379 - Drug-Drug Interaction Study to Investigate Effects of Voclosporin on Pharmacokinetics of Simvastatin Phase 1